This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published on July 11
The full FDA approval for Moderna's pediatric vaccine validates the entire mRNA technology platform, potentially accelerating adoption of similar innovations across multiple companies in this group.
With millions of at-risk children now eligible for fully approved vaccines, companies throughout the healthcare ecosystem stand to benefit from this newly unlocked market segment.
Government focus on protecting vulnerable populations creates a supportive environment for continued investment and innovation in pediatric vaccines and related healthcare services.
Moderna's pediatric vaccine approval is a significant catalyst that expands the market for children's immunization. This regulatory milestone not only benefits direct vaccine manufacturers but creates opportunities throughout the healthcare ecosystem, from research and development to administration and support services.
This group captures the full value chain affected by expanded pediatric vaccination, including mRNA technology developers, adjuvant providers, clinical research organizations, and specialized healthcare services. The FDA approval reduces risk in this market segment and signals potential long-term growth.
These companies were selected because they each play a vital role in the pediatric vaccine rollout. From direct beneficiaries like Moderna to competitors who may see increased interest, and from research organizations to healthcare providers, this collection represents both immediate opportunities and long-term growth potential.
Summary of the basket's total market capitalisation and company-level breakdown, highlighting large-cap concentration.
MRNA: $10.74B
NVAX: $1.40B
CVAC: $1.21B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+5
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
NOVAVAX INC
NVAX
Current Price
$8.71
A key competitor in the COVID-19 vaccine market; full approval for a rival product could increase the focus and potential market for all approved vacc...
A key competitor in the COVID-19 vaccine market; full approval for a rival product could increase the focus and potential market for all approved vaccine manufacturers.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+588.82%
On average, analysts expect assets in this group to grow 588.82% over the next year.
11 of 14 assets in this group are rated Buy by professional analysts.
